Additionally, in the study of Carmona et al. a mutation of AKT3, namely R247C, with a similar activating mechanism as the E17K mutation in AKT1 emerged in a breast cancer during trastuzumab treatment [202]. The gene discussed is AKT3; the disease is breast carcinoma.